Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 11/4/2025

Flecainide Use in Patients with First-Degree Heart Block

Contraindications and Precautions

  • The American College of Cardiology recommends avoiding flecainide in patients with sinus or AV conduction disease, which includes second-degree or third-degree AV block, sick sinus syndrome, and bundle-branch block, due to its potent effects on cardiac conduction 1
  • Flecainide is contraindicated in patients with a history of myocardial infarction, reduced left ventricular ejection fraction, or Brugada syndrome 3
  • The American Heart Association suggests that flecainide should be used with caution in patients with first-degree AV block, as it can worsen conduction abnormalities 1

Clinical Decision Algorithm

  • The American College of Cardiology recommends considering catheter ablation as first-line therapy for patients with first-degree AV block requiring antiarrhythmic therapy, as it avoids pharmacologic conduction risks entirely 2
  • Flecainide may be considered in patients with a PR interval <200 ms, no structural heart disease, normal QRS duration, and normal left ventricular function, but requires careful monitoring 2

Monitoring Requirements

  • The European Heart Journal recommends obtaining baseline ECG, verifying absence of structural heart disease, checking serum electrolytes, and assessing renal and hepatic function before initiating flecainide therapy 3
  • Serial ECGs should be performed to monitor for progressive PR prolongation or QRS widening, and the PR interval should not exceed 300 ms during therapy 4

Pharmacologic Alternatives

  • The American College of Cardiology recommends verapamil or diltiazem as a Class I alternative for AVNRT, and beta-blockers as a Class I alternative for AVNRT 5
  • Sotalol can be used in structural heart disease, but requires QTc monitoring 2

Critical Safety Pitfalls

  • Flecainide carries increased mortality risk in patients with structural heart disease or prior MI, even if asymptomatic, as shown in the Cardiac Arrhythmia Suppression Trial 2
  • Proarrhythmic effects, including atrial flutter with 1:1 AV conduction and ventricular arrhythmias, can occur in 7-8% of patients 1, 3